A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma.
From February 1982 to February 1991, 45 patients with endometrial carcinoma confined to the uterus except for malignant peritoneal cytology were treated with 1 year of progesterone therapy. Thirty-six patients have undergone planned second-look laparoscopy with repeat peritoneal washings and the remaining 9 patients either refused second-look laparoscopy or the procedure was medically contraindicated. Of the 36 who underwent second-look laparoscopy, 34 (94.5%) were NED (no evidence of disease) and had negative repeat peritoneal cytology and 2 (5.5%) had persistent malignant cytology. The latter two patients, after an additional year of progesterone therapy, were found to be NED and had negative peritoneal cytology at third-look laparoscopy. Of the 45 women enrolled in this protocol, no patient has developed recurrent endometrial cancer, and the expected 5-year disease-free survival was 88.6%.
Piver
M S
MS
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263.
Recio
F O
FO
Baker
T R
TR
Hempling
R E
RE
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D006801:Humans; D010535:Laparoscopy; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000556:secondary*; D010537:Peritoneum / Q000473:pathology; D011374:Progesterone / Q000627:therapeutic use*; D011446:Prospective Studies
D011374:Progesterone